Technical Analysis for BMY - Bristol-Myers Squibb Company

Grade Last Price % Change Price Change
F 60.15 1.37% 0.81
BMY closed down 2.32 percent on Thursday, March 4, 2021, on 1.52 times normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical BMY trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 1.42%
20 DMA Resistance Bearish 1.42%
MACD Bearish Signal Line Cross Bearish 1.42%
Expansion Breakdown Bearish Swing Setup 1.42%
Multiple of Ten Bearish Other 1.42%
Down 3 Days in a Row Weakness 1.42%
Lower Bollinger Band Touch Weakness 1.42%
Fell Below 200 DMA Bearish -0.94%
Fell Below 20 DMA Bearish -0.94%
Multiple of Ten Bullish Other -0.94%
Older End-of-Day Signals for BMY ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 3 hours ago
Up 1% about 3 hours ago
1.5x Volume Pace about 5 hours ago
Lower Bollinger Band Support 1 day ago
Down 3% 1 day ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Bristol-Myers Squibb Company Description

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Its principal products include Plavix for protection against fatal or non-fatal heart attack or stroke; Avapro/Avalide for the treatment of hypertension and diabetic nephropathy; Eliquis to prevent and treat venous thromboembolic disorders and stroke prevention in atrial fibrillation; Abilify, an agent for adult patients with schizophrenia, bipolar mania disorder, and depressive disorder; and Reyataz and Sustiva to treat human immunodeficiency virus. The company's products also include Baraclude, an inhibitor of hepatitis B virus; Erbitux to target and block the epidermal growth factor receptor; Sprycel for treatment of chronic myeloid leukemia in adults; Yervoy to treat metastatic melanoma; Orencia to treat adult patients with moderate to severe rheumatoid arthritis; Nulojix to prevent kidney transplant rejection; Onglyza/Kombiglyze, Byetta, and Bydureon to treat type 2 diabetes; and Forxiga for the treatment of diabetes. Its products under Phase III clinical trials include Asunaprevir and Daclatasvir, which are oral small molecule to treat hepatitis C virus infection; Peginterferon lambda, a novel type 3 interferon for hepatitis C virus infection; Elotuzumab for multiple myeloma; and Nivolumab, an anticancer treatment, as well as products under the registrational process comprises Metreleptin for the treatment of lipodystrophy. The company sells its products to wholesalers, as well as directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.


Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Biopharmaceutical Clinics Diabetes Pharmaceutical Products IBD 50 Hypertension Melanoma Rheumatoid Arthritis Schizophrenia Hepatitis B Cancer Treatment Multiple Myeloma Dystrophy Stroke Organic Chemistry Serious Diseases Depressive Disorder Epidermal Growth Factor Receptor Hepatitis C Immunodeficiency Hepatitis B Virus Hepatitis C Virus Diabetic Nephropathy Biopharmaceutical Products Treatment Of Diabetes Atrial Fibrillation Interferon Bristol Myers Squibb Metastatic Melanoma Heart Attack Hepatitis C Virus Infection Kidney Transplant Transplant Rejection Chronic Myeloid Leukemia Leptin Lipodystrophy Treatment Of Hypertension

Is BMY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 67.1599
52 Week Low 45.76
Average Volume 11,186,568
200-Day Moving Average 60.88
50-Day Moving Average 62.16
20-Day Moving Average 60.74
10-Day Moving Average 61.13
Average True Range 1.37
ADX 15.83
+DI 15.59
-DI 29.53
Chandelier Exit (Long, 3 ATRs ) 60.53
Chandelier Exit (Short, 3 ATRs ) 62.73
Upper Bollinger Band 62.43
Lower Bollinger Band 59.05
Percent B (%b) 0.09
BandWidth 5.55
MACD Line -0.40
MACD Signal Line -0.40
MACD Histogram -0.0027
Fundamentals Value
Market Cap 134.09 Billion
Num Shares 2.26 Billion
EPS 0.51
Price-to-Earnings (P/E) Ratio 115.67
Price-to-Sales 3.46
Price-to-Book 2.78
PEG Ratio 0.82
Dividend 1.80
Dividend Yield 3.03%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 62.84
Resistance 3 (R3) 62.99 61.98 62.26
Resistance 2 (R2) 61.98 61.08 61.90 62.06
Resistance 1 (R1) 60.66 60.53 60.15 60.51 61.87
Pivot Point 59.64 59.64 59.39 59.57 59.64
Support 1 (S1) 58.32 58.75 57.82 58.17 56.81
Support 2 (S2) 57.31 58.20 57.23 56.62
Support 3 (S3) 55.99 57.31 56.42
Support 4 (S4) 55.84